|
Kissei funds for MediciNova asthma drug development
Pharmaceutical Business Review Kissei Pharmaceutical is funding $2.5m to support further clinical development of MediciNova's MN-221 to treat acute exacerbations of asthma or chronic obstructive pulmonary disease (COPD). As per the license agreenent signed between the two companies … MediciNova to Receive $2.5 Million Payment From Kissei Pharmaceutical Co. Ltd … Kissei To Pay MediciNova $2.5 Mln To Support Clinical Development Of MN-221 MediciNova Inc expects USD2.5m from Kissei Pharmaceutical Co Ltd for MN-221 … |
View full post on asthma – Google News